Epidemiology and treatment practices of chronic cholestatic liver disease in India: a physician survey-based study
DOI:
https://doi.org/10.18203/issn.2454-2156.IntJSciRep20223372Keywords:
CCLD, Ursodeoxycholic acid, Alcoholic liver disease, Drug-induced liver disease, Liver function testAbstract
Background: Chronic cholestatic liver disease (CCLD) constitutes an intricate array of liver diseases in India. A physician-based survey was conducted to understand the prevalence, current treatment approaches, and gaps in the management of CCLD in India.
Methods: A total of 215 physicians participated to complete a questionnaire comprising 35 questions related to the prevalence and current treatment of CCLD and assess gaps in its management.
Results: Most physicians (53.5%) reported liver disorders with cholestasis to be prevalent in 10-20% of patients, while 34.9% reported their prevalence in 21-30% of patients. Alcoholic liver disease with cholestasis (CCLD [ALD]) was reported in 10-20% of patients and 21-30% of patients by 33.5% and 37.2% of physicians, respectively. Drug-induced liver disease with cholestasis (CCLD [DILI]) was reported to be present in 5-10% of patients by 34.9% of physicians. Ursodeoxycholic acid (UDCA) was found to be used by 60% physicians in >50% of patients with CCLD (ALD), commonly for a period of 4-12 weeks (48.4% physicians), while it was used for 12-24 weeks by 38.1% physicians in CCLD (DILI); for both conditions, the preferred dose was 10-15 mg/kg body weight. UDCA was reported to have good tolerability and efficacy by most physicians for both conditions.
Conclusions: In light of scarce data on CCLD prevalence and management approaches in India, the present survey findings provide useful insights on its prevalence in India and support the use of UDCA therapy for the management of its symptoms.
Metrics
References
Lawate P, Rooprai R, Choudhury G, Dutta S. A prospective, multicentre, observational study of patients with chronic cholestatic liver diseases receiving Udiliv® in India: Splendid study. Int J Basic Clin Pharmacol. 2016;5(6):2621-9.
Mawardi M, Alalwan A, Fallatah H, Abaalkhail F, Hasosah M, Shagrani M et al. Cholestatic liver disease: Practice guidelines from the Saudi Association for the Study of Liver diseases and Transplantation. Saudi J Gastroenterol. 2021;27(7):S1-26.
Tanakaa A, Leung PS, Young HA, Gershwin ME. Toward solving the etiological mystery of primary biliary cholangitis. Hepatol Commun. 2017;1(4):275-87.
Hasegawa S, Yoneda M, Kurita Y, Nogami A, Honda Y, Hosono K et al. Cholestatic liver disease: Current treatment strategies and new therapeutic agents. Drugs. 2021;81(10):1181-92.
Pedersen MR, Mayo MJ. Managing the symptoms and complications of cholestasis. Clin Liver Dis. 2020;15(3):120-24.
Pollock G, Minuk GY. Diagnostic considerations for cholestatic liver disease. J Gastroenterol Hepatol. 2017;32(7):1303-9.
Boonstra K, Beuers U, Ponsioen CY. Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review. J Hepatol. 2012;56(5):1181-8.
Tung BY, Carithers RL Jr. Cholestasis and alcoholic liver disease. Clin Liver Dis. 1999;3(3):585-601.
Wang Q, Huang A, Wang JB, Zou Z. Chronic drug-induced liver injury: Updates and future challenges. Front Pharmacol. 2021;12:627133.
Devarbhavi H, Joseph T, Sunil Kumar N, Rathi C, Thomas V, Prasad Singh S et al. The Indian network of drug-induced liver injury: etiology, clinical features, outcome and prognostic markers in 1288 patients. J Clin Experimental Hepatol. 2021;11(3):288-98.
Mondal D, Das K, Chowdhury A. Epidemiology of liver diseases in India. Clin Liver Dis (Hoboken). 2022;19(3):114-7.
European Association for The Study Of The Liver. EASL Clinical Practice Guidelines: Management of cholestatic liver diseases. J Hepatol. 2009;51(2):237-67.
Heathcote EJ. Management of primary biliary cirrhosis. The American Association for the Study of Liver Diseases practice guidelines. Hepatology. 2000;31(4):1005-13.
Samant H, Manatsathit W, Dies D, Shokouh-Amiri H, Zibari G, Boktor M et al. Cholestatic liver diseases: An era of emerging therapies. World J Clin Cases 2019;7(13):1571-81.
Lindor KD, Kowdley KV, Luketic VA, Harrison ME, McCashland T, Befeler AS et al. High‐dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology. 2009;50(3):808-14.
Mokdad AA, Lopez AD, Shahraz S, Lozano R, Mokdad AH, Stanaway J et al. Liver cirrhosis mortality in 187 countries between 1980 and 2010: A systematic analysis. BMC Med. 2014;12:145.
World Health Organization. Global health estimates: Leading causes of death. Available at: https://www.who.int/data/gho/data/themes/mortality-and-global-health-estimates/ghe-leading-causes-of-death. Accessed on 2022 Nov 8.
Mukherjee PS, Vishnubhatla S, Amarapurkar DN, Das K, Sood A, Chawla YK et al. Etiology and mode of presentation of chronic liver diseases in India: A multi centric study. PLoS One. 2017;12(10):e0187033.
Spahr L, Rubbia-Brandt L, Genevay M, Hadengue A, Giostra E. Early liver biopsy, intraparenchymal cholestasis, and prognosis in patients with alcoholic steatohepatitis. BMC Gastroenterology. 2011;11(1):115.
Torruellas C, French SW, Medici V. Diagnosis of alcoholic liver disease. World J Gastroenterol. 2014;20(33):11684-99.
EASL Clinical Practice Guidelines: Management of alcohol-related liver disease. J Hepatol. 2018;69(1):154-81.
Lee J, Kang HJ, Yoon JH, Lee JM. Ultrasound-guided transient elastography and two-dimensional shear wave elastography for assessment of liver fibrosis: emphasis on technical success and reliable measurements. Ultrasonography. 2021;40(2):217-7.
EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis-2021 update. J Hepatol. 2021;75(3):659-89.
The Asian Pacific Association for the Study of the Liver [APASL] » Guidelines. [cited 2022 Nov 10]. Available at: http://apasl.info/subscription-of-journal/guidelines/. Accessed on 2022 Nov 8.
European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of cholestatic liver diseases. J Hepatol. 2009;51(2):237-67.
European Association for the Study of the Liver. EASL Clinical Practice Guidelines on nutrition in chronic liver disease. J Hepatol. 2019;70(1):172-93.
EASL Clinical Practice Guidelines: Drug-induced liver injury. J Hepatol. 2019;70(6):1222-61.
Podda M, Ghezzi C, Battezzati PM, Bertolini E, Crosignani A, Petroni ML et al. Effect of different doses of ursodeoxycholic acid in chronic liver disease. Digest Dis Sci. 1989;34(12):S59-65.
Kim DJ, Yoon S, Ji SC, Yang J, Kim YK, Lee S et al. Ursodeoxycholic acid improves liver function via phenylalanine/tyrosine pathway and microbiome remodelling in patients with liver dysfunction. Sci Rep. 2018;8(1):11874.
Wunsch E, Raszeja-Wyszomirska J, Barbier O, Milkiewicz M, Krawczyk M, Milkiewicz P. Effect of S-adenosyl-L-methionine on liver biochemistry and quality of life in patients with primary biliary cholangitis treated with ursodeoxycholic acid. A prospective, open label pilot study. J Gastrointestin Liver Dis. 2018;27(3):273-9.
Poupon RE, Balkau B, Eschwège E, Poupon R. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group. N Engl J Med. 1991;324(22):1548-54.
Hirschfield GM, Dyson JK, Alexander GJM, Chapman MH, Collier J, Hübscher S et al. The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines. Gut. 2018;67(9):1568-94.
Simental‐Mendía M, Sánchez‐García A, Simental‐Mendía LE. Effect of ursodeoxycholic acid on liver markers: A systematic review and meta‐analysis of randomized placebo‐controlled clinical trials. Br J Clin Pharmacol. 2020;86(8):1476-88.
Parés A, Caballería L, Rodés J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid. Gastroenterology. 2006;130(3):715-20.
Downloads
Published
How to Cite
Issue
Section
